SMAD7 and ethylmalonic encephalopathy: Despite these limitations, our study demonstrated that SMAD7 expression is increased in EE compared to healthy controls, strengthening the suggestion that therapies targeting SMAD7, such as the Mongersen antisense oligonucleotide, may be viable treatment options in children with EE.